[{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Cypionate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Nasal Gel","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0.02,"dosageForm":"Nasal Spray","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Acerus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Acerus Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activ...

                          Product Name : Natesto

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          October 01, 2022

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Recipient : Verity Pharmaceuticals Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is the first FDA-approved therapy for nocturia.

                          Product Name : Noctiva

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          September 03, 2022

                          Lead Product(s) : Desmopressin Acetate

                          Therapeutic Area : Urology

                          Highest Development Status : Approved FDF

                          Sponsor : Acerus Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          August 02, 2022

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Recipient : University of Utah

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Both Noctiva™ and Natesto® are highly clinically differentiated products with significant patent protection into the 2030s, that Acerus management feels could reach double-digit market share in each of these large market opportunities.

                          Product Name : Noctiva

                          Product Type : Hormone

                          Upfront Cash : $6.0 million

                          February 28, 2022

                          Lead Product(s) : Desmopressin Acetate

                          Therapeutic Area : Urology

                          Highest Development Status : Approved FDF

                          Recipient : Serenity LLC

                          Deal Size : $16.0 million

                          Deal Type : Agreement

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Under the terms of the agreement, Amneal will sell NATESTO, Testosterone Nasal gel to the company’s existing Endocrinology targets through June 30, 2024.

                          Product Name : Natesto

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          October 05, 2021

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Recipient : Amneal Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          July 26, 2021

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Acerus will acquire all remaining rights to Natesto in the United States from Aytu. Acerus will assume all product responsibilities associated with Natesto.

                          Product Name : Natesto

                          Product Type : Hormone

                          Upfront Cash : $7.5 million

                          January 04, 2021

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Recipient : Aytu BioPharma

                          Deal Size : $7.5 million

                          Deal Type : Divestment

                          blank

                          08

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 19, 2020

                          Lead Product(s) : Testosterone Cypionate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Recipient : University of Miami

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          November 17, 2017

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          June 29, 2017

                          Lead Product(s) : Testosterone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Recipient : University of Miami

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank